FDA Delays Action on Much Ballyhooed Weight-Loss Drug Qnexa Citing Late-Arriving REMS
The FDA is delaying its action goal date on Vivus’ obesity drug Qnexa to July 17 after the company’s late submission of a risk evaluation and mitigation strategy (REMS).
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.